Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-6.72%
+35.16%
+1.40%
+4.07%
+0.45%
AXSM
Axsome Therapeutics
$120.26
Login to see Axsome Therapeutics (AXSM) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Earnings are forecast to grow
Outperform the market
Chart
$125.68 (-4.31%)
$112.33 (+7.06%)
$104.25 (+15.36%)
$93.35 (+28.83%)
AXSM has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
AXSM overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
AXSM Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
AXSM Street view is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayAXSM Earnings
The TTM reflects 12-month period, providing review of AXSM financial performance.
The company financial health has moderately improved over the past year
Financial Score
What is AXSM current stock price?
What are AXSM stock strengths?
What risks are associated with AXSM stock?
When is AXSM next earnings report?
What is AXSM market cap and volume?
What is AXSM's current Stock IQ?
Should I buy AXSM stock right now?
Is AXSM a Strong Buy right now?
What does a 'Strong Buy' rating mean for AXSM?
What does a 'Strong Sell' rating mean for AXSM?
What factors influence AXSM's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-6.72%
+35.16%
+1.40%
+4.07%
+0.45%
AXSM
Axsome Therapeutics
Current Price
$120.26
Stock Insights
Strengths
Upgraded on attractively valued
Earnings are forecast to grow
Outperform the market
Login to unlock Axsome Therapeutics (AXSM) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$125.68 (-4.31%)
$112.33 (+7.06%)
$104.25 (+15.36%)
$93.35 (+28.83%)
AXSM Analysts Opinion
AXSM Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
AXSM Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
AXSM Street view is extremely bullish and have negative views on the near-term outlook
AXSM has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayAXSM Earnings
The TTM data reflects the most recent 12-month period, providing overview of AXSM financial performance.
AXSM Financial Health
The company financial health has moderately improved over the past year
Financial Score
AXSM Latest Analysis
Piper Sandler Maintains Overweight on Axsome (AXSM) Sees Growth in AD-Agitation. Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the best biotech stocks to buy. Following a recent discussion with the senior management at Axsome Therapeutics Inc. (NASDAQ:AXSM) Piper Sandler reiterated its Overweight rating on the company and set a price target of $148 on its shares. The firm learned about Axsomes commercial support methods for Auvelity in [….]
Thu Oct 2, 2025
B. Riley Securities Initiates Coverage of Axsome Therapeutics (AXSM) with Buy Recommendation. Fintel reports that on October 1 2025 B. Riley Securities initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy recommendation. Analyst Price Forecast Suggests 51.06% Upside
Thu Oct 2, 2025
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years. Key PointsAxsome Therapeutics lineup already has strong momentum and things will get better as it earns new approvals.
Tue Sep 30, 2025
Axsome Therapeutics Inc. (AXSM) Presents at TD Cowens 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript.
Thu Sep 18, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
AXSM Stock trends
AXSM Stock performance
AXSM Stock analysis
AXSM investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings